Pankreas Cerrahisinde Operabilite
Özet
Pankreas kanseri, agresif biyolojisi ve erken evrede metastaz yapma eğilimi nedeniyle prognozu oldukça zayıf olan ve yüksek mortalite ile seyreden bir malignitedir. Tedavi başarısı ve hastaların sağ kalım süresi, büyük ölçüde negatif cerrahi sınır (R0) sağlanarak yapılan rezeksiyona bağlıdır. Bu nedenle, operasyon öncesi evreleme ve operabilite kriterlerinin doğru değerlendirilmesi hayati önem taşır. Günümüzde hastalar vasküler tutuluma göre rezektabıl, borderline rezektabıl, lokal ileri ve metastatik olarak sınıflandırılmaktadır. Bilgisayarlı Tomografi (BT) ve Manyetik Rezonans Görüntüleme (MRI), tümörün lokalizasyonunu, çevre dokular ve çölyak arter ya da süperior mezenterik arter gibi kritik damarlarla ilişkisini belirlemede en etkin kesitsel yöntemlerdir. Özellikle borderline rezektabıl hastalarda neoadjuvan kemoradyoterapi yaklaşımları, tümör boyutunu küçülterek R0 rezeksiyon şansını ve sağ kalım oranlarını belirgin şekilde artırmaktadır. Ayrıca, bir biyomarker olan CA 19-9 düzeyleri de operabilite ve hastalıksız sağ kalım takibinde güçlü bir prognostik gösterge sunar. Sonuç olarak, pankreas cerrahisinde başarının anahtarı, standart radyolojik şablonlarla doğru hastaların seçilmesi ve multidisipliner yaklaşımdır.
Pancreatic cancer is a highly malignant disease characterized by a poor prognosis and high mortality due to its aggressive biology and propensity for early metastasis. Treatment success and overall survival are heavily dependent on achieving a negative surgical margin (R0) resection. Therefore, accurate preoperative staging and evaluation of operability criteria are of paramount clinical importance. Patients are classified into resectable, borderline resectable, locally advanced, and metastatic stages based on vascular involvement. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) represent the gold standard cross-sectional techniques for delineating tumor localization and its structural relationship with critical vessels such as the celiac artery and superior mesenteric artery. Particularly in borderline resectable cases, neoadjuvant chemoradiotherapy regimens significantly improve survival and the likelihood of successful R0 resection by downsizing tumor extensions. Furthermore, serum CA 19-9 levels serve as a powerful prognostic biomarker for monitoring operability and disease-free survival. In conclusion, optimizing surgical outcomes in pancreatic cancer relies on precise patient selection through standardized radiological reporting templates and robust multidisciplinary coordination.
Referanslar
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473-81.
Chun YS, Pawlik TM, Vauthey JN. 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25:845-7
Chatzizacharias NA, Tsai S, Griffin M, et al. Locally advanced pancreas cancer: staging and goals of therapy. Surgery. 2018;163:1053-62.
Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology. 2014;146(1):291-304.e1.
Pietryga JA, Morgan DE. Imaging preoperatively for pancreatic adenocarcinoma. J Gastrointest Oncol.2015;6(4):343-57.
de la Santa LG, Retortillo JA, Miguel AC, et al. Radiology of pancreatic neoplasms: an update. World J Gastrointest Oncol. 2014;6(9):330-43.
Patel BN, Olcott E, Jeffrey RB. Extrapancreatic perineural invasion in pancreatic adenocarcinoma. Abdom Radiol (NY). 2018;43:323-31.
NCCN clinical practice guidelines in oncology for pancreatik adenocarcinoma. Version 3.2017-September 11, 2017. Available from:https:/www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
Raman SP, Chen Y, Fishman EK. Cross-sectional imaging and the rol of positron emission tomographyin pancreatic cancer evaluation. Semin Oncol. 2015;42(1):40-58.
Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology. 2011;260(2):446-53.
Lee JK, et al. Prediction of vascular involvement and resectability by multidetector-row CT versus MR angiography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma. Eur J Radiol. 2010;73(2):310-6.
Tamm EP, et al. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging. 2006;31(5):568-74.
Fatima J, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145(2):167-72.
Nagakawa T, et al. Patterns of neural and plexus invasion of human pancreatic cancer and experimental cancer. Int J Pancreatol. 1991;10(2):113-9.
Katz MH, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833-46; discussion 846-8.
Christians KK, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19(3):266-74.
Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23(7):1713-22.
Cooper AB, Parmar AD, Riall TS, et al. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? J Gastrointest Surg. 2015;19:80-6; discussion 86-7.
Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2016;35:515-22.
